Login Register Cart 0
Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in Chinese
Review Article

C1-Inhibitor: Structure, Functional Diversity and Therapeutic Development

Author(s): Elena Karnaukhova*

Volume 29, Issue 3, 2022

Published on: 04 August, 2021

Page: [467 - 488] Pages: 22

DOI: 10.2174/0929867328666210804085636

Price: $65

Abstract

Human C1-Inhibitor (C1INH), also known as C1-esterase inhibitor, is an important multifunctional plasma glycoprotein that is uniquely involved in a regulatory network of complement, contact, coagulation, and fibrinolytic systems. C1INH belongs to a superfamily of serine proteinase inhibitors (serpins) and exhibits its inhibitory activities towards several target proteases of plasmatic cascades, operating as a major antiinflammatory protein in the circulation. In addition to its inhibitory activities, C1INH is also involved in non-inhibitory interactions with some endogenous proteins, polyanions, cells and infectious agents. While C1INH is essential for multiple physiological processes, it is better known for its deficiency with regards to Hereditary Angioedema (HAE), a rare autosomal dominant disease clinically manifested by recurrent acute attacks of increased vascular permeability and edema. Since the link was first established between functional C1INH deficiency in plasma and HAE in the 1960s, tremendous progress has been made in the biochemical characterization of C1INH and its therapeutic development for replacement therapies in patients with C1INH-dependent HAE. Various C1INH biological activities, recent advances in the HAE-targeted therapies, and availability of C1INH commercial products have prompted intensive investigation of the C1INH potential for the treatment of clinical conditions other than HAE. This article provides an updated overview of the structural and biological activities of C1INH, its role in HAE pathogenesis, and recent advances in the research and therapeutic development of C1INH; it also considers some trends for using C1INH therapeutic preparations for applications other than angioedema, from sepsis and endotoxin shock to severe thrombotic complications in COVID-19 patients.

Keywords: C1-inhibitor, C1-inhibitor products, complement, contact system, hereditary angioedema, therapeutic development.

« Previous Next »
[1]
Davis, A.E., III; Lu, F.; Mejia, P. C1 inhibitor, a multi-functional serine protease inhibitor. Thromb. Haemost., 2010, 104(5), 886-893.
[PMID: 20806108]
[2]
Wouters, D.; Wagenaar-Bos, I.; van Ham, M.; Zeerleder, S. C1 inhibitor: just a serine protease inhibitor? New and old considerations on therapeutic applications of C1 inhibitor. Expert Opin. Biol. Ther., 2008, 8(8), 1225-1240.
[http://dx.doi.org/10.1517/14712598.8.8.1225] [PMID: 18613773]
[3]
Ratnoff, O.D.; Lepow, I.H. Some properties of an esterase derived from preparations of the first component of complement. J. Exp. Med., 1957, 106(2), 327-343.
[http://dx.doi.org/10.1084/jem.106.2.327] [PMID: 13449241]
[4]
Osler, W. Landmark publication from The American Journal of the Medical Sciences: Hereditary angio-neurotic oedema. Am. J. Med. Sci., 1888, 95, 362-367.
[http://dx.doi.org/10.1097/MAJ.0b013e3181b2803f] [PMID: 20145434]
[5]
deShazo, R.D.; Frank, M.M. Genius at work: Osler’s 1888 article on hereditary angioedema. Am. J. Med. Sci., 2010, 339(2), 179-181.
[http://dx.doi.org/10.1097/MAJ.0b013e3181b28028] [PMID: 20145435]
[6]
Landerman, N.S.; Webster, M.E.; Becker, E.L.; Ratcliffe, H.E. Hereditary angioneurotic edema. II. Deficiency of inhibitor for serum globulin permeability factor and/or plasma kallikrein. J. Allergy, 1962, 33, 330-341.
[http://dx.doi.org/10.1016/0021-8707(62)90032-1] [PMID: 14461960]
[7]
Donaldson, V.H.; Evans, R.R. A biochemical abnormality in herediatry angioneurotic edema: absence of serum inhibitor of c′ 1-esterase. Am. J. Med., 1963, 35, 37-44.
[http://dx.doi.org/10.1016/0002-9343(63)90162-1] [PMID: 14046003]
[8]
Reboul, A.; Arlaud, G.J.; Sim, R.B.; Colomb, M.G. A simplified procedure for the purification of C1-inactivator from human plasma. Interaction with complement subcomponents C1r and C1s. FEBS Lett., 1977, 79(1), 45-50.
[http://dx.doi.org/10.1016/0014-5793(77)80347-5] [PMID: 891934]
[9]
Sim, R.B.; Reboul, A.; Arlaud, G.J.; Villiers, C.L.; Colomb, M.G. Interaction of 125I-labelled complement subcomponents C-1r and C-1s with protease inhibitors in plasma. FEBS Lett., 1979, 97(1), 111-115.
[http://dx.doi.org/10.1016/0014-5793(79)80063-0] [PMID: 761607]
[10]
Sim, R.B.; Arlaud, G.J.; Colomb, M.G. Kinetics of reaction of human C1-inhibitor with the human complement system proteases C1r and C1s. Biochim. Biophys. Acta, 1980, 612(2), 433-449.
[http://dx.doi.org/10.1016/0005-2744(80)90126-6] [PMID: 6245704]
[11]
Ziccardi, R.J. Activation of the early components of the classical complement pathway under physiologic conditions. J. Immunol., 1981, 126(5), 1769-1773.
[PMID: 7217665]
[12]
Bos, I.G.A.; Hack, C.E.; Abrahams, J.P. Structural and functional aspects of C1-inhibitor. Immunobiology, 2002, 205(4-5), 518-533.
[http://dx.doi.org/10.1078/0171-2985-00151] [PMID: 12396012]
[13]
Davis, A.E. III. Mechanism of angioedema in first complement component inhibitor deficiency. Immunol. Allergy Clin. North Am., 2006, 26(4), 633-651.
[http://dx.doi.org/10.1016/j.iac.2006.08.003] [PMID: 17085282]
[14]
Davis, A.E., III New treatments addressing the pathophysiology of hereditary angioedema. Clin. Mol. Allergy, 2008, 6, 2.
[http://dx.doi.org/10.1186/1476-7961-6-2] [PMID: 18410689]
[15]
Karnaukhova, E. C1-esterase inhibitor: biological activities and therapeutic applications. J. Hematol. Thromboembol. Dis, 2013, 1(3), 1-7.
[http://dx.doi.org/10.4172/2329-8790.1000113]
[16]
Gooptu, B.; Lomas, D.A. Conformational pathology of the serpins: themes, variations, and therapeutic strategies. Annu. Rev. Biochem., 2009, 78, 147-176.
[http://dx.doi.org/10.1146/annurev.biochem.78.082107.133320] [PMID: 19245336]
[17]
Silverman, G.A.; Whisstock, J.C.; Bottomley, S.P.; Huntington, J.A.; Kaiserman, D.; Luke, C.J.; Pak, S.C.; Reichhart, J.M.; Bird, P.I. Serpins flex their muscle: I. Putting the clamps on proteolysis in diverse biological systems. J. Biol. Chem., 2010, 285(32), 24299-24305.
[http://dx.doi.org/10.1074/jbc.R110.112771] [PMID: 20498369]
[18]
Katz, Y.; Strunk, R.C. Synthesis and regulation of C1 inhibitor in human skin fibroblasts. J. Immunol., 1989, 142(6), 2041-2045.
[PMID: 2537870]
[19]
Prada, A.E.; Zahedi, K.; Davis, A.E. III. Regulation of C1 inhibitor synthesis. Immunobiology, 1998, 199(2), 377-388.
[http://dx.doi.org/10.1016/S0171-2985(98)80042-9] [PMID: 9777421]
[20]
Schmaier, A.H.; Murray, S.C.; Heda, G.D.; Farber, A.; Kuo, A.; McCrae, K.; Cines, D.B. Synthesis and expression of C1 inhibitor by human umbilical vein endothelial cells. J. Biol. Chem., 1989, 264(30), 18173-18179.
[http://dx.doi.org/10.1016/S0021-9258(19)84693-8] [PMID: 2478540]
[21]
Yeung Laiwah, A.C.; Jones, L.; Hamilton, A.O.; Whaley, K. Complement-subcomponent-C1-inhibitor synthesis by human monocytes. Biochem. J., 1985, 226(1), 199-205.
[http://dx.doi.org/10.1042/bj2260199] [PMID: 3977865]
[22]
Walker, D.G.; Yasuhara, O.; Patston, P.A.; McGeer, E.G.; McGeer, P.L. Complement C1 inhibitor is produced by brain tissue and is cleaved in Alzheimer disease. Brain Res., 1995, 675(1-2), 75-82.
[http://dx.doi.org/10.1016/0006-8993(95)00041-N] [PMID: 7796155]
[23]
Lotz, M.; Zuraw, B.L. Interferon-gamma is a major regulator of C1-inhibitor synthesis by human blood monocytes. J. Immunol., 1987, 139(10), 3382-3387.
[PMID: 3119706]
[24]
Zuraw, B.L.; Lotz, M. Regulation of the hepatic synthesis of C1 inhibitor by the hepatocyte stimulating factors interleukin 6 and interferon gamma. J. Biol. Chem., 1990, 265(21), 12664-12670.
[http://dx.doi.org/10.1016/S0021-9258(19)38395-4] [PMID: 1695634]
[25]
Patston, P.A.; Medcalf, R.L.; Kourteva, Y.; Schapira, M. C1-inhibitor-serine proteinase complexes and the biosynthesis of C1-inhibitor by Hep G2 and U 937 cells. Blood, 1993, 82(11), 3371-3379.
[http://dx.doi.org/10.1182/blood.V82.11.3371.3371] [PMID: 8241507]
[26]
Lappin, D.; Whaley, K. Regulation of C1-inhibitor synthesis by interferons and other agents. Behring Inst. Mitt., 1989, (84), 180-192.
[PMID: 2478116]
[27]
Bock, S.C.; Skriver, K.; Nielsen, E.; Thøgersen, H.C.; Wiman, B.; Donaldson, V.H.; Eddy, R.L.; Marrinan, J.; Radziejewska, E.; Huber, R.; Shows, T.B.; Magnusson, S. Human C1 inhibitor: primary structure, cDNA cloning, and chromosomal localization. Biochem., 1986, 25(15), 4292-4301.
[http://dx.doi.org/10.1021/bi00363a018] [PMID: 3756141]
[28]
Carter, P.E.; Duponchel, C.; Tosi, M.; Fothergill, J.E. Complete nucleotide sequence of the gene for human C1 inhibitor with an unusually high density of Alu elements. Eur. J. Biochem., 1991, 197(2), 301-308.
[http://dx.doi.org/10.1111/j.1432-1033.1991.tb15911.x] [PMID: 2026152]
[29]
Tosi, M. Molecular genetics of C1 inhibitor. Immunobiol., 1998, 199(2), 358-365.
[http://dx.doi.org/10.1016/S0171-2985(98)80040-5] [PMID: 9777419]
[30]
Ponard, D.; Gaboriaud, C.; Charignon, D.; Ghannam, A.; Wagenaar-Bos, I.G.A.; Roem, D.; López-Lera, A.; López-Trascasa, M.; Tosi, M.; Drouet, C. SERPING1 mutation update: Mutation spectrum and C1 Inhibitor phenotypes. Hum. Mutat., 2020, 41(1), 38-57.
[http://dx.doi.org/10.1002/humu.23917] [PMID: 31517426]
[31]
C1 inhibitor gene mutation database. Available from:, http://hae.enzim.hu/
[32]
Bissler, J.J.; Aulak, K.S.; Donaldson, V.H.; Rosen, F.S.; Cicardi, M.; Harrison, R.A.; Davis, A.E. III. Molecular defects in hereditary angioneurotic edema. Proc. Assoc. Am. Physicians, 1997, 109(2), 164-173.
[PMID: 9069585]
[33]
Zuraw, B.L.; Herschbach, J. Detection of C1 inhibitor mutations in patients with hereditary angioedema. J. Allergy Clin. Immunol., 2000, 105(3), 541-546.
[http://dx.doi.org/10.1067/mai.2000.104780] [PMID: 10719305]
[34]
Roche, O.; Blanch, A.; Duponchel, C.; Fontán, G.; Tosi, M.; López-Trascasa, M. Hereditary angioedema: the mutation spectrum of SERPING1/C1NH in a large Spanish cohort. Hum. Mutat., 2005, 26(2), 135-144.
[http://dx.doi.org/10.1002/humu.20197] [PMID: 15971231]
[35]
Gösswein, T.; Kocot, A.; Emmert, G.; Kreuz, W.; Martinez-Saguer, I.; Aygören-Pürsün, E.; Rusicke, E.; Bork, K.; Oldenburg, J.; Müller, C.R. Mutational spectrum of the C1INH (SERPING1) gene in patients with hereditary angioedema. Cytogenet. Genome Res., 2008, 121(3-4), 181-188.
[http://dx.doi.org/10.1159/000138883] [PMID: 18758157]
[36]
Stoppa-Lyonnet, D.; Carter, P.E.; Meo, T.; Tosi, M. Clusters of intragenic Alu repeats predispose the human C1 inhibitor locus to deleterious rearrangements. Proc. Natl. Acad. Sci. USA, 1990, 87(4), 1551-1555.
[http://dx.doi.org/10.1073/pnas.87.4.1551] [PMID: 2154751]
[37]
Skriver, K.; Radziejewska, E.; Silbermann, J.A.; Donaldson, V.H.; Bock, S.C. CpG mutations in the reactive site of human C1 inhibitor. J. Biol. Chem., 1989, 264(6), 3066-3071.
[http://dx.doi.org/10.1016/S0021-9258(18)94031-7] [PMID: 2563376]
[38]
Ennis, S.; Jomary, C.; Mullins, R.; Cree, A.; Chen, X.; Macleod, A.; Jones, S.; Collins, A.; Stone, E.; Lotery, A. Association between the SERPING1 gene and age-related macular degeneration: a two-stage case-control study. Lancet, 2008, 372(9652), 1828-1834.
[http://dx.doi.org/10.1016/S0140-6736(08)61348-3] [PMID: 18842294]
[39]
de Jong, P.T. Age-related macular degeneration. N. Engl. J. Med., 2006, 355(14), 1474-1485.
[http://dx.doi.org/10.1056/NEJMra062326] [PMID: 17021323]
[40]
Mitchell, P.; Liew, G.; Gopinath, B.; Wong, T.Y. Age-related macular degeneration. Lancet, 2018, 392(10153), 1147-1159.
[http://dx.doi.org/10.1016/S0140-6736(18)31550-2] [PMID: 30303083]
[41]
Allikmets, R.; Dean, M.; Hageman, G.S.; Baird, P.N.; Klaver, C.C.; Bergen, A.A.; Weber, B.H. The SERPING1 gene and age-related macular degeneration. Lancet, 2009, 374(9693), 875-876.
[http://dx.doi.org/10.1016/S0140-6736(09)61618-4] [PMID: 19748388]
[42]
Mullins, R.F.; Faidley, E.A.; Daggett, H.T.; Jomary, C.; Lotery, A.J.; Stone, E.M. Localization of complement 1 inhibitor (C1INH/SERPING1) in human eyes with age-related macular degeneration. Exp. Eye Res., 2009, 89(5), 767-773.
[http://dx.doi.org/10.1016/j.exer.2009.07.001] [PMID: 19607829]
[43]
Lee, A.Y.; Kulkarni, M.; Fang, A.M.; Edelstein, S.; Osborn, M.P.; Brantley, M.A. The effect of genetic variants in SERPING1 on the risk of neovascular age-related macular degeneration. Br. J. Ophthalmol., 2010, 94(7), 915-917.
[http://dx.doi.org/10.1136/bjo.2009.172007] [PMID: 20606025]
[44]
Gibson, J.; Hakobyan, S.; Cree, A.J.; Collins, A.; Harris, C.L.; Ennis, S.; Morgan, B.P.; Lotery, A.J. Variation in complement component C1 inhibitor in age-related macular degeneration. Immunobiol., 2012, 217(2), 251-255.
[http://dx.doi.org/10.1016/j.imbio.2011.07.015] [PMID: 21852020]
[45]
Liu, K.; Lai, T.Y.; Ma, L.; Lai, F.H.; Young, A.L.; Brelen, M.E.; Tam, P.O.; Pang, C.P.; Chen, L.J. Ethnic differences in the association of SERPING1 with age-related macular degeneration and polypoidal choroidal vasculopathy. Sci. Rep., 2015, 5, 9424.
[http://dx.doi.org/10.1038/srep09424] [PMID: 25800435]
[46]
Gregorek, H.; Kokai, M.; Hidvégi, T.; Füst, G.; Sabbouh, K.; Madaliński, K. Concentration of C1 inhibitor in sera of healthy blood donors as studied by immunoenzymatic assay. Complement Inflamm., 1991, 8(5-6), 310-312.
[http://dx.doi.org/10.1159/000463201] [PMID: 1802549]
[47]
Zeerleder, S. C1-inhibitor: more than a serine protease inhibitor. Semin. Thromb. Hemost., 2011, 37(4), 362-374.
[http://dx.doi.org/10.1055/s-0031-1276585] [PMID: 21805442]
[48]
Sim, R.B.; Reboul, A. Preparation and properties of human C1 inhibitor. Methods Enzymol., 1981, 80(Pt C), 43-54.
[http://dx.doi.org/10.1016/S0076-6879(81)80007-9] [PMID: 6281621]
[49]
Harrison, R.A. Human C1 inhibitor: improved isolation and preliminary structural characterization. Biochemistry, 1983, 22(21), 5001-5007.
[http://dx.doi.org/10.1021/bi00290a019] [PMID: 6416294]
[50]
Kalter, E.S.; Daha, M.R.; ten Cate, J.W.; Verhoef, J.; Bouma, B.N. Activation and inhibition of Hageman factor-dependent pathways and the complement system in uncomplicated bacteremia or bacterial shock. J. Infect. Dis., 1985, 151(6), 1019-1027.
[http://dx.doi.org/10.1093/infdis/151.6.1019] [PMID: 2582065]
[51]
Woo, P.; Lachmann, P.J.; Harrison, R.A.; Amos, N.; Cooper, C.; Rosen, F.S. Simultaneous turnover of normal and dysfunctional C1 inhibitor as a probe of in vivo activation of C1 and contact activatable proteases. Clin. Exp. Immunol., 1985, 61(1), 1-8.
[PMID: 4042415]
[52]
Nuijens, J.H.; Eerenberg-Belmer, A.J.; Huijbregts, C.C.; Schreuder, W.O.; Felt-Bersma, R.J.; Abbink, J.J.; Thijs, L.G.; Hack, C.E. Proteolytic inactivation of plasma C1- inhibitor in sepsis. J. Clin. Invest., 1989, 84(2), 443-450.
[http://dx.doi.org/10.1172/JCI114185] [PMID: 2668333]
[53]
Windfuhr, J.P.; Alsenz, J.; Loos, M. The critical concentration of C1-esterase inhibitor (C1-INH) in human serum preventing auto-activation of the first component of complement (C1). Mol. Immunol., 2005, 42(6), 657-663.
[http://dx.doi.org/10.1016/j.molimm.2004.09.025] [PMID: 15781109]
[54]
Brackertz, D.; Isler, E.; Kueppers, F. Half-life of C1INH in hereditary angioneurotic oedema (HAE). Clin. Allergy, 1975, 5(1), 89-94.
[http://dx.doi.org/10.1111/j.1365-2222.1975.tb01839.x] [PMID: 1053433]
[55]
Quastel, M.; Harrison, R.; Cicardi, M.; Alper, C.A.; Rosen, F.S. Behavior in vivo of normal and dysfunctional C1 inhibitor in normal subjects and patients with hereditary angioneurotic edema. J. Clin. Invest., 1983, 71(4), 1041-1046.
[http://dx.doi.org/10.1172/JCI110831] [PMID: 6833491]
[56]
Martinez-Saguer, I.; Rusicke, E.; Aygören-Pürsün, E.; von Hentig, N.; Klingebiel, T.; Kreuz, W. Pharmacokinetic analysis of human plasma-derived pasteurized C1-inhibitor concentrate in adults and children with hereditary angioedema: a prospective study. Transfusion, 2010, 50(2), 354-360.
[http://dx.doi.org/10.1111/j.1537-2995.2009.02394.x] [PMID: 19788511]
[57]
Bernstein, J.A.; Ritchie, B.; Levy, R.J.; Wasserman, R.L.; Bewtra, A.K.; Hurewitz, D.S.; Obtulowicz, K.; Reshef, A.; Moldovan, D.; Shirov, T.; Grivcheva-Panovska, V.; Kiessling, P.C.; Schindel, F.; Craig, T.J. Population pharmacokinetics of plasma-derived C1 esterase inhibitor concentrate used to treat acute hereditary angioedema attacks. Ann. Allergy Asthma Immunol., 2010, 105(2), 149-154.
[http://dx.doi.org/10.1016/j.anai.2010.06.005] [PMID: 20674826]
[58]
Bos, I.G.; Lubbers, Y.T.; Roem, D.; Abrahams, J.P.; Hack, C.E.; Eldering, E. The functional integrity of the serpin domain of C1-inhibitor depends on the unique N-terminal domain, as revealed by a pathological mutant. J. Biol. Chem., 2003, 278(32), 29463-29470.
[http://dx.doi.org/10.1074/jbc.M302977200] [PMID: 12773530]
[59]
Liu, D.; Gu, X.; Scafidi, J.; Davis, A.E. III. N-linked glycosylation is required for c1 inhibitor-mediated protection from endotoxin shock in mice. Infect. Immun., 2004, 72(4), 1946-1955.
[http://dx.doi.org/10.1128/IAI.72.4.1946-1955.2004] [PMID: 15039314]
[60]
Perkins, S.J.; Smith, K.F.; Amatayakul, S.; Ashford, D.; Rademacher, T.W.; Dwek, R.A.; Lachmann, P.J.; Harrison, R.A. Two-domain structure of the native and reactive centre cleaved forms of C1 inhibitor of human complement by neutron scattering. J. Mol. Biol., 1990, 214(3), 751-763.
[http://dx.doi.org/10.1016/0022-2836(90)90290-3] [PMID: 2388266]
[61]
Tosi, M.; Duponchel, C.; Bourgarel, P.; Colomb, M.; Meo, T. Molecular cloning of human C1 inhibitor: sequence homologies with alpha 1-antitrypsin and other members of the serpins superfamily. Gene, 1986, 42(3), 265-272.
[http://dx.doi.org/10.1016/0378-1119(86)90230-1] [PMID: 3089875]
[62]
Haupt, H.; Heimburger, N.; Kranz, T.; Schwick, H.G. Isolation and characterization of C1-Inactivator from human plasma. Eur. J. Biochem., 1970, 17(2), 254-261.
[http://dx.doi.org/10.1111/j.1432-1033.1970.tb01161.x]
[63]
Schapira, M.; de Agostini, A.; Schifferli, J.A.; Colman, R.W. Biochemistry and pathophysiology of human C1 inhibitor: current issues. Complement, 1985, 2(2-3), 111-126.
[http://dx.doi.org/10.1159/000467851] [PMID: 3910346]
[64]
Nilsson, T.; Wiman, B. Purification and characterization of human C1-esterase inhibitor. Biochim. Biophys. Acta, 1982, 705(2), 271-276.
[http://dx.doi.org/10.1016/0167-4838(82)90188-1] [PMID: 6981429]
[65]
Wagenaar-Bos, I.G.; Hack, C.E. Structure and function of C1-inhibitor. Immunol. Allergy Clin. North Am., 2006, 26(4), 615-632.
[http://dx.doi.org/10.1016/j.iac.2006.08.004] [PMID: 17085281]
[66]
Rauth, G.; Schumacher, G.; Buckel, P.; Müller-Esterl, W. Molecular cloning of the cDNA coding for human C1 inhibitor. Protein Seq. Data Anal., 1988, 1(4), 251-257.
[PMID: 3393514]
[67]
Perkins, S.J. Three-dimensional structure and molecular modelling of C1- inhibitor. Behring Inst. Mitt., 1993, (93), 63-80.
[PMID: 8172587]
[68]
Beinrohr, L.; Harmat, V.; Dobó, J.; Lörincz, Z.; Gál, P.; Závodszky, P. C1 inhibitor serpin domain structure reveals the likely mechanism of heparin potentiation and conformational disease. J. Biol. Chem., 2007, 282(29), 21100-21109.
[http://dx.doi.org/10.1074/jbc.M700841200] [PMID: 17488724]
[69]
Protein Data Bank. Available from:. https://www.rcsb.org/
[70]
Rajabi, M.; Struble, E.; Zhou, Z.; Karnaukhova, E. Potentiation of C1-esterase inhibitor by heparin and interactions with C1s protease as assessed by surface plasmon resonance. Biochim. Biophys. Acta, 2012, 1820(1), 56-63.
[http://dx.doi.org/10.1016/j.bbagen.2011.10.008] [PMID: 22040724]
[71]
Dijk, M.; Holkers, J.; Voskamp, P.; Giannetti, B.M.; Waterreus, W.J.; van Veen, H.A.; Pannu, N.S. How Dextran Sulfate Affects C1-inhibitor Activity: A Model for Polysaccharide Potentiation. Structure, 2016, 24(12), 2182-2189.
[http://dx.doi.org/10.1016/j.str.2016.09.013] [PMID: 27818099]
[72]
Huntington, J.A.; Read, R.J.; Carrell, R.W. Structure of a serpin-protease complex shows inhibition by deformation. Nature, 2000, 407(6806), 923-926.
[http://dx.doi.org/10.1038/35038119] [PMID: 11057674]
[73]
Caliezi, C.; Wuillemin, W.A.; Zeerleder, S.; Redondo, M.; Eisele, B.; Hack, C.E. C1-Esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol. Rev., 2000, 52(1), 91-112.
[PMID: 10699156]
[74]
Lomas, D.A.; Belorgey, D.; Mallya, M.; Miranda, E.; Kinghorn, K.J.; Sharp, L.K.; Phillips, R.L.; Page, R.; Robertson, A.S.; Crowther, D.C. Molecular mousetraps and the serpinopathies. Biochem. Soc. Trans., 2005, 33(Pt 2), 321-330.
[http://dx.doi.org/10.1042/BST0330321] [PMID: 15787598]
[75]
Huntington, J.A.; Carrell, R.W. The serpins: nature’s molecular mousetraps. Sci. Prog., 2001, 84(Pt 2), 125-136.
[http://dx.doi.org/10.3184/003685001783239032] [PMID: 11525014]
[76]
Harpel, P.C.; Cooper, N.R. Studies on human plasma C1 inactivator-enzyme interactions. I. Mechanisms of interaction with C1s, plasmin, and trypsin. J. Clin. Invest., 1975, 55(3), 593-604.
[http://dx.doi.org/10.1172/JCI107967] [PMID: 123251]
[77]
Cooper, N.R. The classical complement pathway: activation and regulation of the first complement component. Adv. Immunol., 1985, 37, 151-216.
[http://dx.doi.org/10.1016/S0065-2776(08)60340-5] [PMID: 3890478]
[78]
Faulmann, E.L.; Boyle, M.D. Regulation of the activation of C1 in serum. Mol. Immunol., 1987, 24(6), 655-660.
[http://dx.doi.org/10.1016/0161-5890(87)90047-2] [PMID: 3657802]
[79]
Petersen, S.V.; Thiel, S.; Jensen, L.; Vorup-Jensen, T.; Koch, C.; Jensenius, J.C. Control of the classical and the MBL pathway of complement activation. Mol. Immunol., 2000, 37(14), 803-811.
[http://dx.doi.org/10.1016/S0161-5890(01)00004-9] [PMID: 11257302]
[80]
Matsushita, M.; Thiel, S.; Jensenius, J.C.; Terai, I.; Fujita, T. Proteolytic activities of two types of mannose-binding lectin-associated serine protease. J. Immunol., 2000, 165(5), 2637-2642.
[http://dx.doi.org/10.4049/jimmunol.165.5.2637] [PMID: 10946292]
[81]
Schapira, M.; Scott, C.F.; Colman, R.W. Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma. J. Clin. Invest., 1982, 69(2), 462-468.
[http://dx.doi.org/10.1172/JCI110470] [PMID: 6173399]
[82]
de Agostini, A.; Lijnen, H.R.; Pixley, R.A.; Colman, R.W.; Schapira, M. Inactivation of factor XII active fragment in normal plasma. Predominant role of C-1-inhibitor. J. Clin. Invest., 1984, 73(6), 1542-1549.
[http://dx.doi.org/10.1172/JCI111360] [PMID: 6725552]
[83]
Pixley, R.A.; Schapira, M.; Colman, R.W. The regulation of human factor XIIa by plasma proteinase inhibitors. J. Biol. Chem., 1985, 260(3), 1723-1729.
[http://dx.doi.org/10.1016/S0021-9258(18)89653-3] [PMID: 2578463]
[84]
Kaplan, A.P. Enzymatic pathways in the pathogenesis of hereditary angioedema: the role of C1 inhibitor therapy. J. Allergy Clin. Immunol., 2010, 126(5), 918-925.
[http://dx.doi.org/10.1016/j.jaci.2010.08.012] [PMID: 20889195]
[85]
Kaplan, A.P.; Ghebrehiwet, B. The plasma bradykinin-forming pathways and its interrelationships with complement. Mol. Immunol., 2010, 47(13), 2161-2169.
[http://dx.doi.org/10.1016/j.molimm.2010.05.010] [PMID: 20580091]
[86]
Huisman, L.G.; van Griensven, J.M.; Kluft, C. On the role of C1-inhibitor as inhibitor of tissue-type plasminogen activator in human plasma. Thromb. Haemost., 1995, 73(3), 466-471.
[http://dx.doi.org/10.1055/s-0038-1653798] [PMID: 7667830]
[87]
Van Nostrand, W.E.; McKay, L.D.; Baker, J.B.; Cunningham, D.D. Functional and structural similarities between protease nexin I and C1 inhibitor. J. Biol. Chem., 1988, 263(8), 3979-3983.
[http://dx.doi.org/10.1016/S0021-9258(18)69022-2] [PMID: 3279027]
[88]
Wuillemin, W.A.; Minnema, M.; Meijers, J.C.; Roem, D.; Eerenberg, A.J.; Nuijens, J.H.; ten Cate, H.; Hack, C.E. Inactivation of factor XIa in human plasma assessed by measuring factor XIa-protease inhibitor complexes: major role for C1-inhibitor. Blood, 1995, 85(6), 1517-1526.
[http://dx.doi.org/10.1182/blood.V85.6.1517.bloodjournal8561517] [PMID: 7534133]
[89]
Cugno, M.; Bos, I.; Lubbers, Y.; Hack, C.E.; Agostoni, A. In vitro interaction of C1-inhibitor with thrombin. Blood Coagul. Fibrinolysis, 2001, 12(4), 253-260.
[http://dx.doi.org/10.1097/00001721-200106000-00005] [PMID: 11460008]
[90]
Caccia, S.; Castelli, R.; Maiocchi, D.; Bergamaschini, L.; Cugno, M. Interaction of C1 inhibitor with thrombin on the endothelial surface. Blood Coagul. Fibrinolysis, 2011, 22(7), 571-575.
[http://dx.doi.org/10.1097/MBC.0b013e3283494ba7] [PMID: 21959589]
[91]
Caughman, G.B.; Boackle, R.J.; Vesely, J. A postulated mechanism for heparin’s potentiation of C1 inhibitor function. Mol. Immunol., 1982, 19(2), 287-295.
[http://dx.doi.org/10.1016/0161-5890(82)90342-X] [PMID: 7099168]
[92]
Boackle, R.J.; Caughman, G.B.; Vesely, J.; Medgyesi, G.; Fudenberg, H.H. Potentiation of factor H by heparin: a rate-limiting mechanism for inhibition of the alternative complement pathway. Mol. Immunol., 1983, 20(11), 1157-1164.
[http://dx.doi.org/10.1016/0161-5890(83)90139-6] [PMID: 6228720]
[93]
Wuillemin, W.A.; te Velthuis, H.; Lubbers, Y.T.; de Ruig, C.P.; Eldering, E.; Hack, C.E. Potentiation of C1 inhibitor by glycosaminoglycans: dextran sulfate species are effective inhibitors of in vitro complement activation in plasma. J. Immunol., 1997, 159(4), 1953-1960.
[PMID: 9257861]
[94]
Pixley, R.A.; Schmaier, A.; Colman, R.W. Effect of negatively charged activating compounds on inactivation of factor XIIa by Cl inhibitor. Arch. Biochem. Biophys., 1987, 256(2), 490-498.
[http://dx.doi.org/10.1016/0003-9861(87)90606-0] [PMID: 3497611]
[95]
Lennick, M.; Brew, S.A.; Ingham, K.C. Kinetics of interaction of C1 inhibitor with complement C1s. Biochemistry, 1986, 25(13), 3890-3898.
[http://dx.doi.org/10.1021/bi00361a023] [PMID: 3091067]
[96]
Nilsson, T.; Wiman, B. Kinetics of the reaction between human C1-esterase inhibitor and C1r or C1s. Eur. J. Biochem., 1983, 129(3), 663-667.
[http://dx.doi.org/10.1111/j.1432-1033.1983.tb07100.x] [PMID: 6297891]
[97]
Wuillemin, W.A.; Eldering, E.; Citarella, F.; de Ruig, C.P.; ten Cate, H.; Hack, C.E. Modulation of contact system proteases by glycosaminoglycans. Selective enhancement of the inhibition of factor XIa. J. Biol. Chem., 1996, 271(22), 12913-12918.
[http://dx.doi.org/10.1074/jbc.271.22.12913] [PMID: 8662679]
[98]
Caldwell, E.E.; Andreasen, A.M.; Blietz, M.A.; Serrahn, J.N.; VanderNoot, V.; Park, Y.; Yu, G.; Linhardt, R.J.; Weiler, J.M. Heparin binding and augmentation of C1 inhibitor activity. Arch. Biochem. Biophys., 1999, 361(2), 215-222.
[http://dx.doi.org/10.1006/abbi.1998.0996] [PMID: 9882449]
[99]
Poppelaars, F.; Damman, J.; de Vrij, E.L.; Burgerhof, J.G.; Saye, J.; Daha, M.R.; Leuvenink, H.G.; Uknis, M.E.; Seelen, M.A. New insight into the effects of heparinoids on complement inhibition by C1-inhibitor. Clin. Exp. Immunol., 2016, 184(3), 378-388.
[http://dx.doi.org/10.1111/cei.12777] [PMID: 26874675]
[100]
Yu, H.; Muñoz, E.M.; Edens, R.E.; Linhardt, R.J. Kinetic studies on the interactions of heparin and complement proteins using surface plasmon resonance. Biochim. Biophys. Acta, 2005, 1726(2), 168-176.
[http://dx.doi.org/10.1016/j.bbagen.2005.08.003] [PMID: 16125850]
[101]
Rossi, V.; Bally, I.; Ancelet, S.; Xu, Y.; Frémeaux-Bacchi, V.; Vivès, R.R.; Sadir, R.; Thielens, N.; Arlaud, G.J. Functional characterization of the recombinant human C1 inhibitor serpin domain: insights into heparin binding. J. Immunol., 2010, 184(9), 4982-4989.
[http://dx.doi.org/10.4049/jimmunol.0902016] [PMID: 20351192]
[102]
Schoenfeld, A.K.; Lahrsen, E.; Alban, S. Regulation of Complement and Contact System Activation via C1 Inhibitor Potentiation and Factor XIIa Activity Modulation by Sulfated Glycans - Structure-Activity Relationships. PLoS One, 2016, 11(10)e0165493
[http://dx.doi.org/10.1371/journal.pone.0165493] [PMID: 27783665]
[103]
Blossom, D.B.; Kallen, A.J.; Patel, P.R.; Elward, A.; Robinson, L.; Gao, G.; Langer, R.; Perkins, K.M.; Jaeger, J.L.; Kurkjian, K.M.; Jones, M.; Schillie, S.F.; Shehab, N.; Ketterer, D.; Venkataraman, G.; Kishimoto, T.K.; Shriver, Z.; McMahon, A.W.; Austen, K.F.; Kozlowski, S.; Srinivasan, A.; Turabelidze, G.; Gould, C.V.; Arduino, M.J.; Sasisekharan, R. Outbreak of adverse reactions associated with contaminated heparin. N. Engl. J. Med., 2008, 359(25), 2674-2684.
[http://dx.doi.org/10.1056/NEJMoa0806450] [PMID: 19052120]
[104]
Kishimoto, T.K.; Viswanathan, K.; Ganguly, T.; Elankumaran, S.; Smith, S.; Pelzer, K.; Lansing, J.C.; Sriranganathan, N.; Zhao, G.; Galcheva-Gargova, Z.; Al-Hakim, A.; Bailey, G.S.; Fraser, B.; Roy, S.; Rogers-Cotrone, T.; Buhse, L.; Whary, M.; Fox, J.; Nasr, M.; Dal Pan, G.J.; Shriver, Z.; Langer, R.S.; Venkataraman, G.; Austen, K.F.; Woodcock, J.; Sasisekharan, R. Contaminated heparin associated with adverse clinical events and activation of the contact system. N. Engl. J. Med., 2008, 358(23), 2457-2467.
[http://dx.doi.org/10.1056/NEJMoa0803200] [PMID: 18434646]
[105]
Zhou, Z.H.; Rajabi, M.; Chen, T.; Karnaukhova, E.; Kozlowski, S. Oversulfated chondroitin sulfate inhibits the complement classical pathway by potentiating C1 inhibitor. PLoS One, 2012, 7(10)e47296
[http://dx.doi.org/10.1371/journal.pone.0047296] [PMID: 23077587]
[106]
Wijeyewickrema, L.C.; Lameignere, E.; Hor, L.; Duncan, R.C.; Shiba, T.; Travers, R.J.; Kapopara, P.R.; Lei, V.; Smith, S.A.; Kim, H.; Morrissey, J.H.; Pike, R.N.; Conway, E.M. Polyphosphate is a novel cofactor for regulation of complement by a serpin, C1 inhibitor. Blood, 2016, 128(13), 1766-1776.
[http://dx.doi.org/10.1182/blood-2016-02-699561] [PMID: 27338096]
[107]
Conway, E.M. Polyphosphates and Complement Activation. Front. Med. (Lausanne), 2019, 6, 67.[Lausanne]..
[http://dx.doi.org/10.3389/fmed.2019.00067] [PMID: 31019911]
[108]
Hor, L.; Pan, J.; Whisstock, J.C.; Pike, R.N.; Wijeyewickrema, L.C. Mapping the binding site of C1-inhibitor for polyanion cofactors. Mol. Immunol., 2020, 126, 8-13.
[http://dx.doi.org/10.1016/j.molimm.2020.06.018] [PMID: 32717572]
[109]
Frank, M.M.; Gelfand, J.A.; Atkinson, J.P. Hereditary angioedema: the clinical syndrome and its management. Ann. Intern. Med., 1976, 84(5), 580-593.
[http://dx.doi.org/10.7326/0003-4819-84-5-580] [PMID: 1275365]
[110]
Zuraw, B.L. Clinical practice. Hereditary angioedema. N. Engl. J. Med., 2008, 359(10), 1027-1036.
[http://dx.doi.org/10.1056/NEJMcp0803977] [PMID: 18768946]
[111]
Tourangeau, L.M.; Zuraw, B.L. The new era of C1-esterase inhibitor deficiency therapy. Curr. Allergy Asthma Rep., 2011, 11(5), 345-351.
[http://dx.doi.org/10.1007/s11882-011-0213-8] [PMID: 21833753]
[112]
Agostoni, A.; Aygören-Pürsün, E.; Binkley, K.E.; Blanch, A.; Bork, K.; Bouillet, L.; Bucher, C.; Castaldo, A.J.; Cicardi, M.; Davis, A.E.; De Carolis, C.; Drouet, C.; Duponchel, C.; Farkas, H.; Fáy, K.; Fekete, B.; Fischer, B.; Fontana, L.; Füst, G.; Giacomelli, R.; Gröner, A.; Hack, C.E.; Harmat, G.; Jakenfelds, J.; Juers, M.; Kalmár, L.; Kaposi, P.N.; Karádi, I.; Kitzinger, A.; Kollár, T.; Kreuz, W.; Lakatos, P.; Longhurst, H.J.; Lopez-Trascasa, M.; Martinez-Saguer, I.; Monnier, N.; Nagy, I.; Németh, E.; Nielsen, E.W.; Nuijens, J.H.; O’grady, C.; Pappalardo, E.; Penna, V.; Perricone, C.; Perricone, R.; Rauch, U.; Roche, O.; Rusicke, E.; Späth, P.J.; Szendei, G.; Takács, E.; Tordai, A.; Truedsson, L.; Varga, L.; Visy, B.; Williams, K.; Zanichelli, A.; Zingale, L. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J. Allergy Clin. Immunol., 2004, 114(3)(Suppl.), S51-S131.
[http://dx.doi.org/10.1016/j.jaci.2004.06.047] [PMID: 15356535]
[113]
Banerji, A. Hereditary angioedema: classification, pathogenesis, and diagnosis. Allergy Asthma Proc., 2011, 32(6), 403-407.
[http://dx.doi.org/10.2500/aap.2011.32.3492] [PMID: 22221432]
[114]
Maurer, M.; Magerl, M.; Ansotegui, I.; Aygören-Pürsün, E.; Betschel, S.; Bork, K.; Bowen, T.; Balle Boysen, H.; Farkas, H.; Grumach, A.S.; Hide, M.; Katelaris, C.; Lockey, R.; Longhurst, H.; Lumry, W.R.; Martinez-Saguer, I.; Moldovan, D.; Nast, A.; Pawankar, R.; Potter, P.; Riedl, M.; Ritchie, B.; Rosenwasser, L.; Sánchez-Borges, M.; Zhi, Y.; Zuraw, B.; Craig, T. The international WAO/EAACI guideline for the management of hereditary angioedema-The 2017 revision and update. Allergy, 2018, 73(8), 1575-1596.
[http://dx.doi.org/10.1111/all.13384] [PMID: 29318628]
[115]
Bork, K.; Barnstedt, S.E.; Koch, P.; Traupe, H. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet, 2000, 356(9225), 213-217.
[http://dx.doi.org/10.1016/S0140-6736(00)02483-1] [PMID: 10963200]
[116]
Dewald, G.; Bork, K. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem. Biophys. Res. Commun., 2006, 343(4), 1286-1289.
[http://dx.doi.org/10.1016/j.bbrc.2006.03.092] [PMID: 16638441]
[117]
Cichon, S.; Martin, L.; Hennies, H.C.; Müller, F.; Van Driessche, K.; Karpushova, A.; Stevens, W.; Colombo, R.; Renné, T.; Drouet, C.; Bork, K.; Nöthen, M.M. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am. J. Hum. Genet., 2006, 79(6), 1098-1104.
[http://dx.doi.org/10.1086/509899] [PMID: 17186468]
[118]
Bork, K.; Machnig, T.; Wulff, K.; Witzke, G.; Prusty, S.; Hardt, J. Clinical features of genetically characterized types of hereditary angioedema with normal C1 inhibitor: a systematic review of qualitative evidence. Orphanet J. Rare Dis., 2020, 15(1), 289.
[http://dx.doi.org/10.1186/s13023-020-01570-x] [PMID: 33059692]
[119]
Riedl, M.A. Hereditary angioedema with normal C1-INH (HAE type III). J. Allergy Clin. Immunol. Pract., 2013, 1(5), 427-432.
[http://dx.doi.org/10.1016/j.jaip.2013.06.004] [PMID: 24565612]
[120]
Cugno, M.; Castelli, R.; Cicardi, M. Angioedema due to acquired C1-inhibitor deficiency: a bridging condition between autoimmunity and lymphoproliferation. Autoimmun. Rev., 2008, 8(2), 156-159.
[http://dx.doi.org/10.1016/j.autrev.2008.05.003] [PMID: 19014872]
[121]
Cugno, M.; Zanichelli, A.; Foieni, F.; Caccia, S.; Cicardi, M. C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. Trends Mol. Med., 2009, 15(2), 69-78.
[http://dx.doi.org/10.1016/j.molmed.2008.12.001] [PMID: 19162547]
[122]
Patel, G.; Pongracic, J.A. Hereditary and acquired angioedema. Allergy Asthma Proc., 2019, 40(6), 441-445.
[http://dx.doi.org/10.2500/aap.2019.40.4267] [PMID: 31690390]
[123]
Zeerleder, S.; Levi, M. Hereditary and acquired C1-inhibitor-dependent angioedema: from pathophysiology to treatment. Ann. Med., 2016, 48(4), 256-267.
[http://dx.doi.org/10.3109/07853890.2016.1162909] [PMID: 27018196]
[124]
Longhurst, H.; Cicardi, M. Hereditary angio-oedema. Lancet, 2012, 379(9814), 474-481.
[http://dx.doi.org/10.1016/S0140-6736(11)60935-5] [PMID: 22305226]
[125]
Kaplan, A.P.; Joseph, K. Pathogenesis of Hereditary Angioedema: The Role of the Bradykinin-Forming Cascade. Immunol. Allergy Clin. North Am., 2017, 37(3), 513-525.
[http://dx.doi.org/10.1016/j.iac.2017.04.001] [PMID: 28687106]
[126]
Kaplan, A.P.; Joseph, K. Complement, Kinins, and Hereditary Angioedema: Mechanisms of Plasma Instability when C1 Inhibitor is Absent. Clin. Rev. Allergy Immunol., 2016, 51(2), 207-215.
[http://dx.doi.org/10.1007/s12016-016-8555-6] [PMID: 27273087]
[127]
Henry Li, H.; Riedl, M.; Kashkin, J. Update on the Use of C1-Esterase Inhibitor Replacement Therapy in the Acute and Prophylactic Treatment of Hereditary Angioedema. Clin. Rev. Allergy Immunol., 2019, 56(2), 207-218.
[http://dx.doi.org/10.1007/s12016-018-8684-1] [PMID: 29909591]
[128]
Bork, K.; Kleist, R.; Hardt, J.; Witzke, G. Kallikrein-kinin system and fibrinolysis in hereditary angioedema due to factor XII gene mutation Thr309Lys. Blood Coagul. Fibrinolysis, 2009, 20(5), 325-332.
[http://dx.doi.org/10.1097/MBC.0b013e32832811f8] [PMID: 19474702]
[129]
Levi, M.; Cohn, D.M. The Role of Complement in Hereditary Angioedema. Transfus. Med. Rev., 2019, 33(4), 243-247.
[http://dx.doi.org/10.1016/j.tmrv.2019.08.002] [PMID: 31676220]
[130]
Bossi, F.; Peerschke, E.I.; Ghebrehiwet, B.; Tedesco, F. Cross-talk between the complement and the kinin system in vascular permeability. Immunol. Lett., 2011, 140(1-2), 7-13.
[http://dx.doi.org/10.1016/j.imlet.2011.06.006] [PMID: 21762728]
[131]
Csuka, D.; Munthe-Fog, L.; Skjoedt, M.O.; Kocsis, A.; Zotter, Z.; Gál, P.; Varga, L.; Farkas, H.; Füst, G.; Garred, P. The role of ficolins and MASPs in hereditary angioedema due to C1-inhibitor deficiency. Mol. Immunol., 2013, 54(3-4), 271-277.
[http://dx.doi.org/10.1016/j.molimm.2012.12.015] [PMID: 23318225]
[132]
Cugno, M.; Hack, C.E.; de Boer, J.P.; Eerenberg, A.J.; Agostoni, A.; Cicardi, M. Generation of plasmin during acute attacks of hereditary angioedema. J. Lab. Clin. Med., 1993, 121(1), 38-43.
[PMID: 8426080]
[133]
Cugno, M.; Cicardi, M.; Bottasso, B.; Coppola, R.; Paonessa, R.; Mannucci, P.M.; Agostoni, A. Activation of the coagulation cascade in C1-inhibitor deficiencies. Blood, 1997, 89(9), 3213-3218.
[http://dx.doi.org/10.1182/blood.V89.9.3213] [PMID: 9129025]
[134]
Nielsen, E.W.; Johansen, H.T.; Høgåsen, K.; Wuillemin, W.; Hack, C.E.; Mollnes, T.E. Activation of the complement, coagulation, fibrinolytic and kallikrein-kinin systems during attacks of hereditary angioedema. Scand. J. Immunol., 1996, 44(2), 185-192.
[http://dx.doi.org/10.1046/j.1365-3083.1996.d01-298.x] [PMID: 8711433]
[135]
Bork, K.; Meng, G.; Staubach, P.; Hardt, J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am. J. Med., 2006, 119(3), 267-274.
[http://dx.doi.org/10.1016/j.amjmed.2005.09.064] [PMID: 16490473]
[136]
Zuraw, B.L.; Christiansen, S.C. Pathophysiology of hereditary angioedema. Am. J. Rhinol. Allergy, 2011, 25(6), 373-378.
[http://dx.doi.org/10.2500/ajra.2011.25.3661] [PMID: 22185738]
[137]
Cicardi, M.; Bork, K.; Caballero, T.; Craig, T.; Li, H.H.; Longhurst, H.; Reshef, A.; Zuraw, B. Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy, 2012, 67(2), 147-157.
[http://dx.doi.org/10.1111/j.1398-9995.2011.02751.x] [PMID: 22126399]
[138]
Cicardi, M.; Johnston, D.T. Hereditary and acquired complement component 1 esterase inhibitor deficiency: a review for the hematologist. Acta Haematol., 2012, 127(4), 208-220.
[http://dx.doi.org/10.1159/000336590] [PMID: 22456031]
[139]
Lumry, W.R. Current and emerging therapies to prevent hereditary angioedema attacks. Am. J. Manag. Care, 2018, 24(14)(Suppl.), S299-S307.
[PMID: 30132644]
[140]
Longhurst, H.J.; Bork, K. Hereditary angioedema: an update on causes, manifestations and treatment. Br. J. Hosp. Med. (Lond.), 2019, 80(7), 391-398.
[http://dx.doi.org/10.12968/hmed.2019.80.7.391] [PMID: 31283393]
[141]
Nicola, S.; Rolla, G.; Brussino, L. Breakthroughs in hereditary angioedema management: a systematic review of approved drugs and those under research. Drugs Context, 2019, 8212605
[PMID: 31645881]
[142]
Busse, P.J.; Christiansen, S.C. Hereditary Angioedema. N. Engl. J. Med., 2020, 382(12), 1136-1148.
[http://dx.doi.org/10.1056/NEJMra1808012] [PMID: 32187470]
[143]
Longhurst, H.; Farkas, H. Biological therapy in hereditary angioedema: transformation of a rare disease. Expert Opin. Biol. Ther., 2020, 20(5), 493-501.
[http://dx.doi.org/10.1080/14712598.2020.1724280] [PMID: 31994957]
[144]
Zuraw, B.L. HAE therapies: past present and future. Allergy Asthma Clin. Immunol., 2010, 6(1), 23.
[http://dx.doi.org/10.1186/1710-1492-6-23] [PMID: 20667126]
[145]
Buyantseva, L.V.; Sardana, N.; Craig, T.J. Update on treatment of hereditary angioedema. Asian Pac. J. Allergy Immunol., 2012, 30(2), 89-98.
[PMID: 22830287]
[146]
Hsu, D.; Shaker, M. An update on hereditary angioedema. Curr. Opin. Pediatr., 2012, 24(5), 638-646.
[http://dx.doi.org/10.1097/MOP.0b013e328357b25e] [PMID: 22935756]
[147]
Lumry, W.; Templeton, T.; Omert, L.; Levy, D. Advances in Hereditary Angioedema: The Prevention of Angioedema Attacks With Subcutaneous C1-Inhibitor Replacement Therapy. J. Infus. Nurs., 2020, 43(3), 134-145.
[http://dx.doi.org/10.1097/NAN.0000000000000365] [PMID: 32287168]
[148]
Brackertz, D.; Kueppers, F. Hereditary angioneurotic oedema. Lancet, 1973, 2(7830), 680.
[http://dx.doi.org/10.1016/S0140-6736(73)92519-1] [PMID: 4125654]
[149]
ViroPharma Biologics LLC, Takeda Pharmaceuticals U.S.A. Inc. CINRYZE: highlights of prescribing information. Available from: . http://pi.shirecontent.com/PI/PDFs/Cinryze_USA_ENG.pdf
[150]
Sanquin Cetor: Patient information., Available from:. http://www.haenet.hu/doc/patient/Cetor%20Patient%20information.pdf
[151]
CSL Behring, Berinert (C1-esterase Inhibitor) highlights of prescribing information. Available from:, https://labeling. cslbehring.com/PI/US/Berinert/EN/Berinert-Prescribing-Information.pdf
[152]
Pharming Intellectual Property, B.V. RUCONEST (C1 esterase inhibitor [recombinant]): highlights of prescribing information. Available from:. https://www.ruconest.com/wp-content/uploads/Ruconest_PI_20Dec2019.pdf
[153]
CSL Behring, Haegarda (C1-esterase Inhibitor [Human]): highlights of prescribing information. Available from:. https://labeling.cslbehring.com/PI/US/HAEGARDA/EN/HAEGARDA-Prescribing-Information.pdf
[154]
Joseph, K.; Tholanikunnel, T.E.; Kaplan, A.P. Treatment of episodes of hereditary angioedema with C1 inhibitor: serial assessment of observed abnormalities of the plasma bradykinin-forming pathway and fibrinolysis. Ann. Allergy Asthma Immunol., 2010, 104(1), 50-54.
[http://dx.doi.org/10.1016/j.anai.2009.11.014] [PMID: 20143645]
[155]
Longhurst, H.; Cicardi, M.; Craig, T.; Bork, K.; Grattan, C.; Baker, J.; Li, H.H.; Reshef, A.; Bonner, J.; Bernstein, J.A.; Anderson, J.; Lumry, W.R.; Farkas, H.; Katelaris, C.H.; Sussman, G.L.; Jacobs, J.; Riedl, M.; Manning, M.E.; Hebert, J.; Keith, P.K.; Kivity, S.; Neri, S.; Levy, D.S.; Baeza, M.L.; Nathan, R.; Schwartz, L.B.; Caballero, T.; Yang, W.; Crisan, I.; Hernandez, M.D.; Hussain, I.; Tarzi, M.; Ritchie, B.; Králíčková, P.; Guilarte, M.; Rehman, S.M.; Banerji, A.; Gower, R.G.; Bensen-Kennedy, D.; Edelman, J.; Feuersenger, H.; Lawo, J.P.; Machnig, T.; Pawaskar, D.; Pragst, I.; Zuraw, B.L. Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor. N. Engl. J. Med., 2017, 376(12), 1131-1140.
[http://dx.doi.org/10.1056/NEJMoa1613627] [PMID: 28328347]
[156]
Craig, T.; Zuraw, B.; Longhurst, H.; Cicardi, M.; Bork, K.; Grattan, C.; Katelaris, C.; Sussman, G.; Keith, P.K.; Yang, W.; Hébert, J.; Hanzlikova, J.; Staubach-Renz, P.; Martinez-Saguer, I.; Magerl, M.; Aygören-Pürsün, E.; Farkas, H.; Reshef, A.; Kivity, S.; Neri, S.; Crisan, I.; Caballero, T.; Baeza, M.L.; Hernandez, M.D.; Li, H.; Lumry, W.; Bernstein, J.A.; Hussain, I.; Anderson, J.; Schwartz, L.B.; Jacobs, J.; Manning, M.; Levy, D.; Riedl, M.; Christiansen, S.; Feuersenger, H.; Pragst, I.; Mycroft, S.; Pawaskar, D.; Jacobs, I. COMPACT Investigators. Long-term outcomes with subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks. J. Allergy Clin. Immunol. Pract., 2019, 7(6), 1793-1802.
[http://dx.doi.org/10.1016/j.jaip.2019.01.054] [PMID: 30772477]
[157]
Levy, D.S.; Farkas, H.; Riedl, M.A.; Hsu, F.I.; Brooks, J.P.; Cicardi, M.; Feuersenger, H.; Pragst, I.; Reshef, A. Long-term efficacy and safety of subcutaneous C1-inhibitor in women with hereditary angioedema: subgroup analysis from an open-label extension of a phase 3 trial. Allergy Asthma Clin. Immunol., 2020, 16, 8.
[http://dx.doi.org/10.1186/s13223-020-0409-3] [PMID: 32042283]
[158]
Riedl, M.A.; Lumry, W.R.; Li, H.H.; Banerji, A.; Bernstein, J.A.; Ba, M.; Bjrkander, J.; Magerl, M.; Maurer, M.; Rockich, K.; Chen, H.; Schranz, J. Subcutaneous administration of human C1 inhibitor with recombinant human hyaluronidase in patients with hereditary angioedema. Allergy Asthma Proc., 2016, 37(6), 489-500.
[http://dx.doi.org/10.2500/aap.2016.37.4006] [PMID: 27931305]
[159]
Weller, K.; Maurer, M.; Fridman, M.; Supina, D.; Schranz, J.; Magerl, M. Health-related quality of life with hereditary angioedema following prophylaxis with subcutaneous C1-inhibitor with recombinant hyaluronidase. Allergy Asthma Proc., 2017, 38(2), 143-151.
[http://dx.doi.org/10.2500/aap.2017.38.4025] [PMID: 28093999]
[160]
Menzel, E.J.; Farr, C. Hyaluronidase and its substrate hyaluronan: biochemistry, biological activities and therapeutic uses. Cancer Lett., 1998, 131(1), 3-11.
[http://dx.doi.org/10.1016/S0304-3835(98)00195-5] [PMID: 9839614]
[161]
Weber, G.C.; Buhren, B.A.; Schrumpf, H.; Wohlrab, J.; Gerber, P.A. Clinical Applications of Hyaluronidase. Adv. Exp. Med. Biol., 2019, 1148, 255-277.
[http://dx.doi.org/10.1007/978-981-13-7709-9_12] [PMID: 31482503]
[162]
Eldering, E.; Nuijens, J.H.; Hack, C.E. Expression of functional human C1 inhibitor in COS cells. J. Biol. Chem., 1988, 263(24), 11776-11779.
[http://dx.doi.org/10.1016/S0021-9258(18)37851-7] [PMID: 2841334]
[163]
Eldering, E.; Huijbregts, C.C.; Lubbers, Y.T.; Longstaff, C.; Hack, C.E. Characterization of recombinant C1 inhibitor P1 variants. J. Biol. Chem., 1992, 267(10), 7013-7020.
[http://dx.doi.org/10.1016/S0021-9258(19)50529-4] [PMID: 1551909]
[164]
Lamark, T.; Ingebrigtsen, M.; Bjørnstad, C.; Melkko, T.; Mollnes, T.E.; Nielsen, E.W. Expression of active human C1 inhibitor serpin domain in Escherichia coli. Protein Expr. Purif., 2001, 22(2), 349-358.
[http://dx.doi.org/10.1006/prep.2001.1445] [PMID: 11437612]
[165]
Wolff, M.W.; Zhang, F.; Roberg, J.J.; Caldwell, E.E.; Kaul, P.R.; Serrahn, J.N.; Murhammer, D.W.; Linhardt, R.J.; Weiler, J.M. Expression of C1 esterase inhibitor by the baculovirus expression vector system: preparation, purification, and characterization. Protein Expr. Purif., 2001, 22(3), 414-421.
[http://dx.doi.org/10.1006/prep.2001.1461] [PMID: 11483003]
[166]
Bos, I.G.; de Bruin, E.C.; Karuntu, Y.A.; Modderman, P.W.; Eldering, E.; Hack, C.E. Recombinant human C1-inhibitor produced in Pichia pastoris has the same inhibitory capacity as plasma C1-inhibitor. Biochim. Biophys. Acta, 2003, 1648(1-2), 75-83.
[http://dx.doi.org/10.1016/S1570-9639(03)00107-9] [PMID: 12758149]
[167]
van Doorn, M.B.; Burggraaf, J.; van Dam, T.; Eerenberg, A.; Levi, M.; Hack, C.E.; Schoemaker, R.C.; Cohen, A.F.; Nuijens, J. A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. J. Allergy Clin. Immunol., 2005, 116(4), 876-883.
[http://dx.doi.org/10.1016/j.jaci.2005.05.019] [PMID: 16210064]
[168]
Choi, G.; Soeters, M.R.; Farkas, H.; Varga, L.; Obtulowicz, K.; Bilo, B.; Porebski, G.; Hack, C.E.; Verdonk, R.; Nuijens, J.; Levi, M. Recombinant human C1-inhibitor in the treatment of acute angioedema attacks. Transfusion, 2007, 47(6), 1028-1032.
[http://dx.doi.org/10.1111/j.1537-2995.2007.01239.x] [PMID: 17524093]
[169]
Houdebine, L.M. Production of pharmaceutical proteins by transgenic animals. Rev. Sci. Tech., 2018, 37(1), 131-139.
[http://dx.doi.org/10.20506/rst.37.1.2746] [PMID: 30209423]
[170]
van Veen, H.A.; Koiter, J.; Vogelezang, C.J.; van Wessel, N.; van Dam, T.; Velterop, I.; van Houdt, K.; Kupers, L.; Horbach, D.; Salaheddine, M.; Nuijens, J.H.; Mannesse, M.L. Characterization of recombinant human C1 inhibitor secreted in milk of transgenic rabbits. J. Biotechnol., 2012, 162(2-3), 319-326.
[http://dx.doi.org/10.1016/j.jbiotec.2012.09.005] [PMID: 22995741]
[171]
Riedl, M. Recombinant human C1 esterase inhibitor in the management of hereditary angioedema. Clin. Drug Investig., 2015, 35(7), 407-417.
[http://dx.doi.org/10.1007/s40261-015-0300-z] [PMID: 26091744]
[172]
Koles, K.; van Berkel, P.H.; Pieper, F.R.; Nuijens, J.H.; Mannesse, M.L.; Vliegenthart, J.F.; Kamerling, J.P. N- and O-glycans of recombinant human C1 inhibitor expressed in the milk of transgenic rabbits. Glycobiology, 2004, 14(1), 51-64.
[http://dx.doi.org/10.1093/glycob/cwh010] [PMID: 14514717]
[173]
Relan, A.; Bakhtiari, K.; van Amersfoort, E.S.; Meijers, J.C.; Hack, C.E. Recombinant C1-inhibitor: effects on coagulation and fibrinolysis in patients with hereditary angioedema. BioDrugs, 2012, 26(1), 43-52.
[http://dx.doi.org/10.2165/11599490-000000000-00000] [PMID: 22171564]
[174]
Plosker, G.L. Recombinant human c1 inhibitor (conestat alfa): in the treatment of angioedema attacks in hereditary angioedema. BioDrugs, 2012, 26(5), 315-323.
[http://dx.doi.org/10.1007/BF03261889] [PMID: 22946752]
[175]
Valerieva, A.; Caccia, S.; Cicardi, M. Recombinant human C1 esterase inhibitor (Conestat alfa) for prophylaxis to prevent attacks in adult and adolescent patients with hereditary angioedema. Expert Rev. Clin. Immunol., 2018, 14(9), 707-718.
[http://dx.doi.org/10.1080/1744666X.2018.1503055] [PMID: 30021471]
[176]
Pensky, J.; Levy, L.R.; Lepow, I.H. Partial purification of a serum inhibitor of C’1-esterase. J. Biol. Chem., 1961, 236, 1674-1679.
[http://dx.doi.org/10.1016/S0021-9258(19)63283-7] [PMID: 13734157]
[177]
Over, J.; Kramer, C.; Koenderman, A.; Wouters, D.; Zeerleder, S. C1-inhibitor.In: Production of plasma proteins for therapeutic use; Bertolini, J.; Goss, N.; Curling, J., Eds.; John Wiley: New York, 2013, pp. 241-258.
[http://dx.doi.org/10.1002/9781118356807.ch17]
[178]
Simon, T.L.; Kalina, U.; Laske, R.; Mycroft, S.; Widmer, E.; Roth, N.J. Manufacturing of plasma-derived C1-inhibitor concentrate for treatment of patients with hereditary angioedema. Allergy Asthma Proc., 2020, 41(2), 99-107.
[http://dx.doi.org/10.2500/aap.2020.41.190021] [PMID: 31796151]
[179]
WHO 1st International Standard for C1-inhibitor, concentrate, NIBSC code: 08/256. 2020. Available from:. www.nibsc.org/documents/ifu/08-256.pdf
[180]
Thelwel, C.; Rigsby, P.; Longstaff, C. An international collaborative study to establish the WHO 1st international standards for C1-inhibitor, plasma and concentrate. J. Thromb. Haemost., 2011, 9(10), 2097-2099.
[http://dx.doi.org/10.1111/j.1538-7836.2011.04455.x] [PMID: 22053337]
[181]
Gröner, A.; Nowak, T.; Schäfer, W. Pathogen safety of human C1 esterase inhibitor concentrate. Transfusion, 2012, 52(10), 2104-2112.
[http://dx.doi.org/10.1111/j.1537-2995.2012.03590.x] [PMID: 22413956]
[182]
Roth, N.J. Pathogen reduction of blood components and plasma derivatives.Rossi’s principles of transfusion medicine; Simon, T.L.; McCullough, J.; Snyder, E.L.; Solheim, B.G.; Strauss, R.G., Eds.; John Wiley: London, 2016, pp. 632-641.
[http://dx.doi.org/10.1002/9781119013020.ch56]
[183]
Riedl, M.A.; Bygum, A.; Lumry, W.; Magerl, M.; Bernstein, J.A.; Busse, P.; Craig, T.; Frank, M.M.; Edelman, J.; Williams-Herman, D.; Feuersenger, H.; Rojavin, M. Berinert Registry investigators. Safety and usage of C1-inhibitor in hereditary angioedema: berinert registry data. J. Allergy Clin. Immunol. Pract., 2016, 4(5), 963-971.
[http://dx.doi.org/10.1016/j.jaip.2016.04.018] [PMID: 27286778]
[184]
Feussner, A.; Kalina, U.; Hofmann, P.; Machnig, T.; Henkel, G. Biochemical comparison of four commercially available C1 esterase inhibitor concentrates for treatment of hereditary angioedema. Transfusion, 2014, 54(10), 2566-2573.
[http://dx.doi.org/10.1111/trf.12678] [PMID: 24805006]
[185]
Gandhi, P.K.; Gentry, W.M.; Bottorff, M.B. Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database. Pharmacotherapy, 2012, 32(10), 902-909.
[http://dx.doi.org/10.1002/j.1875-9114.2012.01126] [PMID: 23033229]
[186]
Crowther, M.; Bauer, K.A.; Kaplan, A.P. The thrombogenicity of C1 esterase inhibitor (human): review of the evidence. Allergy Asthma Proc., 2014, 35(6), 444-453.
[http://dx.doi.org/10.2500/aap.2014.35.3799] [PMID: 25584911]
[187]
Farkas, H.; Kőhalmi, K.V.; Veszeli, N.; Zotter, Z.; Várnai, K.; Varga, L. Risk of thromboembolism in patients with hereditary angioedema treated with plasma-derived C1-inhibitor. Allergy Asthma Proc., 2016, 37(2), 164-170.
[http://dx.doi.org/10.2500/aap.2016.37.3933] [PMID: 26802388]
[188]
Burnham, K.; Reinert, J.P. Thromboembolic Risk of C1 Esterase Inhibitors: A Systematic Review on Current Evidence. Expert Rev. Clin. Pharmacol., 2020, 13(7), 779-786.
[http://dx.doi.org/10.1080/17512433.2020.1776110] [PMID: 32476505]
[189]
Tarandovskiy, I.D.; Buehler, P.W.; Ataullakhanov, F.I.; Karnaukhova, E. C1-esterase inhibitor enhances thrombin generation and spatial fibrin clot propagation in the presence of thrombomodulin. Thromb. Res., 2019, 176, 54-60.
[http://dx.doi.org/10.1016/j.thromres.2019.02.013] [PMID: 30784776]
[190]
Tarandovskiy, I.D.; Rajabi, A.A.; Karnaukhova, E.; Buehler, P.W. Contradictory to its effects on thrombin, C1-inhibitor reduces plasmin generation in the presence of thrombomodulin. J. Thromb. Thrombolysis, 2019, 48(1), 81-87.
[http://dx.doi.org/10.1007/s11239-019-01869-y] [PMID: 31030323]
[191]
Riedl, M. Hereditary angioedema therapies in the United States: movement toward an international treatment consensus. Clin. Ther., 2012, 34(3), 623-630.
[http://dx.doi.org/10.1016/j.clinthera.2012.02.003] [PMID: 22386830]
[192]
Charignon, D.; Späth, P.; Martin, L.; Drouet, C. Icatibant, the bradykinin B2 receptor antagonist with target to the interconnected kinin systems. Expert Opin. Pharmacother., 2012, 13(15), 2233-2247.
[http://dx.doi.org/10.1517/14656566.2012.723692] [PMID: 22970904]
[193]
Wu, M.A. Lanadelumab for the treatment of hereditary angioedema. Expert Opin. Biol. Ther., 2019, 19(12), 1233-1245.
[http://dx.doi.org/10.1080/14712598.2019.1685490] [PMID: 31657963]
[194]
Croner, R.S.; Lehmann, T.G.; Fallsehr, C.; Herfarth, C.; Klar, E.; Kirschfink, M. C1-inhibitor reduces hepatic leukocyte-endothelial interaction and the expression of VCAM-1 in LPS-induced sepsis in the rat. Microvasc. Res., 2004, 67(2), 182-191.
[http://dx.doi.org/10.1016/j.mvr.2003.09.009] [PMID: 15020209]
[195]
Fischer, M.B.; Prodeus, A.P.; Nicholson-Weller, A.; Ma, M.; Murrow, J.; Reid, R.R.; Warren, H.B.; Lage, A.L.; Moore, F.D., Jr; Rosen, F.S.; Carroll, M.C. Increased susceptibility to endotoxin shock in complement C3- and C4-deficient mice is corrected by C1 inhibitor replacement. J. Immunol., 1997, 159(2), 976-982.
[PMID: 9218619]
[196]
Jansen, P.M.; Eisele, B.; de Jong, I.W.; Chang, A.; Delvos, U.; Taylor, F.B., Jr; Hack, C.E. Effect of C1 inhibitor on inflammatory and physiologic response patterns in primates suffering from lethal septic shock. J. Immunol., 1998, 160(1), 475-484.
[PMID: 9552006]
[197]
Liu, D.; Cai, S.; Gu, X.; Scafidi, J.; Wu, X.; Davis, A.E. III. C1 inhibitor prevents endotoxin shock via a direct interaction with lipopolysaccharide. J. Immunol., 2003, 171(5), 2594-2601.
[http://dx.doi.org/10.4049/jimmunol.171.5.2594] [PMID: 12928411]
[198]
Liu, D.; Lu, F.; Qin, G.; Fernandes, S.M.; Li, J.; Davis, A.E. III. C1 inhibitor-mediated protection from sepsis. J. Immunol., 2007, 179(6), 3966-3972.
[http://dx.doi.org/10.4049/jimmunol.179.6.3966] [PMID: 17785834]
[199]
Hack, C.E.; Voerman, H.J.; Eisele, B.; Keinecke, H.O.; Nuijens, J.H.; Eerenberg, A.J.; Ogilvie, A.; Strack van Schijndel, R.J.; Delvos, U.; Thijs, L.G. C1-esterase inhibitor substitution in sepsis. Lancet, 1992, 339(8789), 378.
[http://dx.doi.org/10.1016/0140-6736(92)91705-D] [PMID: 1346464]
[200]
Hack, C.E.; Ogilvie, A.C.; Eisele, B.; Jansen, P.M.; Wagstaff, J.; Thijs, L.G. Initial studies on the administration of C1-esterase inhibitor to patients with septic shock or with a vascular leak syndrome induced by interleukin-2 therapy. Prog. Clin. Biol. Res., 1994, 388, 335-357.
[PMID: 7831367]
[201]
Caliezi, C.; Zeerleder, S.; Redondo, M.; Regli, B.; Rothen, H.U.; Zürcher-Zenklusen, R.; Rieben, R.; Devay, J.; Hack, C.E.; Lämmle, B.; Wuillemin, W.A. C1-inhibitor in patients with severe sepsis and septic shock: beneficial effect on renal dysfunction. Crit. Care Med., 2002, 30(8), 1722-1728.
[http://dx.doi.org/10.1097/00003246-200208000-00008] [PMID: 12163783]
[202]
Zeerleder, S.; Caliezi, C.; van Mierlo, G.; Eerenberg-Belmer, A.; Sulzer, I.; Hack, C.E.; Wuillemin, W.A. Administration of C1 inhibitor reduces neutrophil activation in patients with sepsis. Clin. Diagn. Lab. Immunol., 2003, 10(4), 529-535.
[PMID: 12853381]
[203]
Igonin, A.A.; Protsenko, D.N.; Galstyan, G.M.; Vlasenko, A.V.; Khachatryan, N.N.; Nekhaev, I.V.; Shlyapnikov, S.A.; Lazareva, N.B.; Herscu, P. C1-esterase inhibitor infusion increases survival rates for patients with sepsis*. Crit. Care Med., 2012, 40(3), 770-777.
[http://dx.doi.org/10.1097/CCM.0b013e318236edb8] [PMID: 22080632]
[204]
Tapisiz, A.; Ergenekon, E.; Oktem, M.; Koc, E.; Okumus, N.; Zenciroğlu, A.; Atalay, Y. C1 inhibitor level on neonatal sepsis and its relations with clinical findings. J. Paediatr. Child Health, 2010, 46(3), 121-124.
[http://dx.doi.org/10.1111/j.1440-1754.2009.01649.x] [PMID: 20180898]
[205]
Buerke, M.; Murohara, T.; Lefer, A.M. Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion. Circulation, 1995, 91(2), 393-402.
[http://dx.doi.org/10.1161/01.CIR.91.2.393] [PMID: 7805243]
[206]
Buerke, M.; Prüfer, D.; Dahm, M.; Oelert, H.; Meyer, J.; Darius, H. Blocking of classical complement pathway inhibits endothelial adhesion molecule expression and preserves ischemic myocardium from reperfusion injury. J. Pharmacol. Exp. Ther., 1998, 286(1), 429-438.
[PMID: 9655888]
[207]
Fu, J.; Lin, G.; Wu, Z.; Ceng, B.; Wu, Y.; Liang, G.; Qin, G.; Li, J.; Chiu, I.; Liu, D. Anti-apoptotic role for C1 inhibitor in ischemia/reperfusion-induced myocardial cell injury. Biochem. Biophys. Res. Commun., 2006, 349(2), 504-512.
[http://dx.doi.org/10.1016/j.bbrc.2006.08.065] [PMID: 16942749]
[208]
Fu, J.; Lin, G.; Zeng, B.; Wu, Z.; Wu, Y.; Chu, H.; Qin, G.; Liang, G.; Li, J.; Gan, X.; Yu, X.; Li, C.; Liu, D. Anti-ischemia/reperfusion of C1 inhibitor in myocardial cell injury via regulation of local myocardial C3 activity. Biochem. Biophys. Res. Commun., 2006, 350(1), 162-168.
[http://dx.doi.org/10.1016/j.bbrc.2006.09.023] [PMID: 16996480]
[209]
Bauernschmitt, R.; Böhrer, H.; Hagl, S. Rescue therapy with C1-esterase inhibitor concentrate after emergency coronary surgery for failed PTCA. Intensive Care Med., 1998, 24(6), 635-638.
[http://dx.doi.org/10.1007/s001340050629] [PMID: 9681790]
[210]
de Zwaan, C.; Kleine, A.H.; Diris, J.H.; Glatz, J.F.; Wellens, H.J.; Strengers, P.F.; Tissing, M.; Hack, C.E.; van Dieijen-Visser, M.P.; Hermens, W.T. Continuous 48-h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction. Eur. Heart J., 2002, 23(21), 1670-1677.
[http://dx.doi.org/10.1053/euhj.2002.3191] [PMID: 12398824]
[211]
Thielmann, M.; Marggraf, G.; Neuhäuser, M.; Forkel, J.; Herold, U.; Kamler, M.; Massoudy, P.; Jakob, H. Administration of C1-esterase inhibitor during emergency coronary artery bypass surgery in acute ST-elevation myocardial infarction. Eur. J. Cardiothorac. Surg., 2006, 30(2), 285-293.
[http://dx.doi.org/10.1016/j.ejcts.2006.04.022] [PMID: 16829095]
[212]
Fattouch, K.; Bianco, G.; Speziale, G.; Sampognaro, R.; Lavalle, C.; Guccione, F.; Dioguardi, P.; Ruvolo, G. Beneficial effects of C1 esterase inhibitor in ST-elevation myocardial infarction in patients who underwent surgical reperfusion: a randomised double-blind study. Eur. J. Cardiothorac. Surg., 2007, 32(2), 326-332.
[http://dx.doi.org/10.1016/j.ejcts.2007.04.038] [PMID: 17576071]
[213]
Fiane, A.E.; Videm, V.; Johansen, H.T.; Mellbye, O.J.; Nielsen, E.W.; Mollnes, T.E. C1-inhibitor attenuates hyperacute rejection and inhibits complement, leukocyte and platelet activation in an ex vivo pig-to-human perfusion model. Immunopharmacology, 1999, 42(1-3), 231-243.
[http://dx.doi.org/10.1016/S0162-3109(99)00008-9] [PMID: 10408384]
[214]
Pöling, J.; Oezkur, M.; Kogge, K.; Mengel, M.; Niemann, H.; Winkler, M.; Haverich, A.; Wiebe, K. Hyperacute rejection in ex vivo-perfused porcine lungs transgenic for human complement regulatory proteins. Transpl. Int., 2006, 19(3), 225-232.
[http://dx.doi.org/10.1111/j.1432-2277.2006.00267.x] [PMID: 16441772]
[215]
Schelzig, H.; Simon, F.; Krischer, C.; Vogel, A.; Abendroth, D. Ex-vivo hemoperfusion (eHPS) of pig-lungs with whole human blood: effects of complement inhibition with a soluble C1-esterase-inhibitor. Ann. Transplant., 2001, 6(3), 34-39.
[PMID: 11899895]
[216]
Hecker, J.M.; Loss, M.; Klempnauer, J.; Winkler, M. C1-inhibitor for therapy and prophylaxis of acute vascular rejection of porcine kidneys in cynomolgus monkeys. Transplant. Proc., 2002, 34(6), 2382.
[http://dx.doi.org/10.1016/S0041-1345(02)03280-3] [PMID: 12270447]
[217]
Hecker, J.M.; Lorenz, R.; Appiah, R.; Vangerow, B.; Loss, M.; Kunz, R.; Schmidtko, J.; Mengel, M.; Klempnauer, J.; Piepenbrock, S.; Dickneite, G.; Neidhardt, H.; Rückoldt, H.; Winkler, M. C1-inhibitor for prophylaxis of xenograft rejection after pig to cynomolgus monkey kidney transplantation. Transplantation, 2002, 73(5), 688-694.
[http://dx.doi.org/10.1097/00007890-200203150-00006] [PMID: 11907412]
[218]
Schröder, C.; Pfeiffer, S.; Wu, G.; Zorn, G.L., III; Ding, L.; Allen, C.; Harrison, R.A.; White, D.J.; Azimzadeh, A.M.; Pierson, R.N., III Effect of complement fragment 1 esterase inhibition on survival of human decay-accelerating factor pig lungs perfused with human blood. J. Heart Lung Transplant., 2003, 22(12), 1365-1375.
[http://dx.doi.org/10.1016/S1053-2498(03)00026-3] [PMID: 14672751]
[219]
Nürnberger, W.; Heying, R.; Burdach, S.; Göbel, U. C1 esterase inhibitor concentrate for capillary leakage syndrome following bone marrow transplantation. Ann. Hematol., 1997, 75(3), 95-101.
[http://dx.doi.org/10.1007/s002770050321] [PMID: 9368478]
[220]
Strüber, M.; Hagl, C.; Hirt, S.W.; Cremer, J.; Harringer, W.; Haverich, A. C1-esterase inhibitor in graft failure after lung transplantation. Intensive Care Med., 1999, 25(11), 1315-1318.
[http://dx.doi.org/10.1007/s001340051065] [PMID: 10654221]
[221]
Niederau, C.; Brinsa, R.; Niederau, M.; Lüthen, R.; Strohmeyer, G.; Ferrell, L.D. Effects of C1-esterase inhibitor in three models of acute pancreatitis. Int. J. Pancreatol., 1995, 17(2), 189-196.
[PMID: 7622941]
[222]
Hack, C.E.; Ogilvie, A.C.; Eisele, B.; Eerenberg, A.J.; Wagstaff, J.; Thijs, L.G. C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2. Intensive Care Med., 1993, 19(Suppl. 1), S19-S28.
[http://dx.doi.org/10.1007/BF01738946] [PMID: 8053997]
[223]
Zwijnenburg, P.J.; van der Poll, T.; Florquin, S.; Polfliet, M.M.; van den Berg, T.K.; Dijkstra, C.D.; Roord, J.J.; Hack, C.E.; van Furth, A.M. C1 inhibitor treatment improves host defense in pneumococcal meningitis in rats and mice. J. Infect. Dis., 2007, 196(1), 115-123.
[http://dx.doi.org/10.1086/518609] [PMID: 17538891]
[224]
Cicardi, M.; Zingale, L.; Zanichelli, A.; Pappalardo, E.; Cicardi, B. C1 inhibitor: molecular and clinical aspects. Springer Semin. Immunopathol., 2005, 27(3), 286-298.
[http://dx.doi.org/10.1007/s00281-005-0001-4] [PMID: 16267649]
[225]
Singer, M.; Jones, A.M. Bench-to-bedside review: the role of C1-esterase inhibitor in sepsis and other critical illnesses. Crit. Care, 2011, 15(1), 203.
[http://dx.doi.org/10.1186/cc9304] [PMID: 21345278]
[226]
McFadyen, J.D.; Stevens, H.; Peter, K. The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications. Circ. Res., 2020, 127(4), 571-587.
[http://dx.doi.org/10.1161/CIRCRESAHA.120.317447] [PMID: 32586214]
[227]
Noris, M.; Benigni, A.; Remuzzi, G. The case of complement activation in COVID-19 multiorgan impact. Kidney Int., 2020, 98(2), 314-322.
[http://dx.doi.org/10.1016/j.kint.2020.05.013] [PMID: 32461141]
[228]
Lo, M.W.; Kemper, C.; Woodruff, T.M. COVID-19: complement, coagulation, and collateral damage. J. Immunol., 2020, 205(6), 1488-1495.
[http://dx.doi.org/10.4049/jimmunol.2000644] [PMID: 32699160]
[229]
Colling, M.E.; Kanthi, Y. COVID-19-associated coagulopathy: An exploration of mechanisms. Vasc. Med., 2020, 25(5), 471-478.
[http://dx.doi.org/10.1177/1358863X20932640] [PMID: 32558620]
[230]
Lippi, G.; Sanchis-Gomar, F.; Henry, B.M. COVID-19: unravelling the clinical progression of nature’s virtually perfect biological weapon. Ann. Transl. Med., 2020, 8(11), 693.
[http://dx.doi.org/10.21037/atm-20-3989] [PMID: 32617313]
[231]
Mackman, N.; Antoniak, S.; Wolberg, A.S.; Kasthuri, R.; Key, N.S. Coagulation Abnormalities and Thrombosis in Patients Infected With SARS-CoV-2 and Other Pandemic Viruses. Arterioscler. Thromb. Vasc. Biol., 2020, 40(9), 2033-2044.
[http://dx.doi.org/10.1161/ATVBAHA.120.314514] [PMID: 32657623]
[232]
Stahel, P.F.; Barnum, S.R. Complement Inhibition in Coronavirus Disease (COVID)-19: A Neglected Therapeutic Option. Front. Immunol., 2020, 11, 1661.
[http://dx.doi.org/10.3389/fimmu.2020.01661] [PMID: 32733489]
[233]
Thomson, T.M.; Toscano-Guerra, E.; Casis, E.; Paciucci, R. C1 esterase inhibitor and the contact system in COVID-19. Br. J. Haematol., 2020, 190(4), 520-524.
[http://dx.doi.org/10.1111/bjh.16938] [PMID: 32531085]
[234]
Meini, S.; Zanichelli, A.; Sbrojavacca, R.; Iuri, F.; Roberts, A.T.; Suffritti, C.; Tascini, C. Understanding the Pathophysiology of COVID-19: Could the Contact System Be the Key? Front. Immunol., 2020, 11, 2014.
[http://dx.doi.org/10.3389/fimmu.2020.02014] [PMID: 32849666]
[235]
Fletcher-Sandersjöö, A.; Bellander, B.M. Is COVID-19 associated thrombosis caused by overactivation of the complement cascade? A literature review. Thromb. Res., 2020, 194, 36-41.
[http://dx.doi.org/10.1016/j.thromres.2020.06.027] [PMID: 32569879]
[236]
Campbell, C.M.; Kahwash, R. Will complement inhibition be the new target in treating COVID-19-related systemic thrombosis? Circulation, 2020, 141(22), 1739-1741.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.120.047419] [PMID: 32271624]
[237]
Xu, Y.; Liu, S.; Zhang, Y.; Zhi, Y. Does hereditary angioedema make COVID-19 worse? World Allergy Organ. J., 2020, 13(9)100454
[http://dx.doi.org/10.1016/j.waojou.2020.100454] [PMID: 32834893]
[238]
Urwyler, P.; Moser, S.; Charitos, P.; Heijnen, I.A.F.M.; Rudin, M.; Sommer, G.; Giannetti, B.M.; Bassetti, S.; Sendi, P.; Trendelenburg, M.; Osthoff, M. Treatment of COVID-19 with conestat alfa, a regulator of the complement, contact activation and kallikrein-kinin system. Front. Immunol., 2020, 11, 2072.
[http://dx.doi.org/10.3389/fimmu.2020.02072] [PMID: 32922409]
[239]
Mansour, E.; Palma, A.C.; Ulaf, R.G.; Ribeiro, L.C.; Bernardes, A.F.; Nunes, T.A.; Agrela, M.V.; Bombassaro, B.; Monfort-Pires, M.; Camargo, R.L.; Araujo, E.P.; Brunetti, N.S.; Farias, A.S.; Falcao, A.L.; Santos, T.M.; Trabasso, P.; Dertkigil, R.P.; Dertkigil, S.S.; Moretti, M.L.; Velloso, L. A Pharmacological inhibition of the kinin-kallikrein system in severe COVID-19. A proof-of-concept study; MedRxiv, 2020.
[http://dx.doi.org/10.1101/2020.08.11.20167353]
[240]
Urwyler, P.; Charitos, P.; Moser, S.; Heijnen, I.A.F.M.; Trendelenburg, M.; Thoma, R.; Sumer, J.; Camacho-Ortiz, A.; Bacci, M.R.; Huber, L.C.; Stüssi-Helbling, M.; Albrich, W.C.; Sendi, P.; Osthoff, M. Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19). Trials, 2021, 22(1), 1.
[http://dx.doi.org/10.1186/s13063-020-04976-x] [PMID: 33397449]
[241]
Mansour, E.; Bueno, F.F.; de Lima-Júnior, J.C.; Palma, A.; Monfort-Pires, M.; Bombassaro, B.; Araujo, E.P.; Bernardes, A.F.; Ulaf, R.G.; Nunes, T.A.; Ribeiro, L.C.; Falcão, A.L.E.; Santos, T.M.; Trabasso, P.; Dertkigil, R.P.; Dertkigil, S.S.; Maia, R.P.; Benaglia, T.; Moretti, M.L.; Velloso, L.A. Evaluation of the efficacy and safety of icatibant and C1 esterase/kallikrein inhibitor in severe COVID-19: study protocol for a three-armed randomized controlled trial. Trials, 2021, 22(1), 71.
[http://dx.doi.org/10.1186/s13063-021-05027-9] [PMID: 33472675]
[242]
Chen, L.; Xiong, J.; Bao, L.; Shi, Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect. Dis., 2020, 20(4), 398-400.
[http://dx.doi.org/10.1016/S1473-3099(20)30141-9] [PMID: 32113510]

Rights & Permissions Print Cite
Article Metrics
95
2
World Chagas Disease
© 2024 Bentham Science Publishers | Privacy Policy